Nobelpharma America

Nobelpharma America is a pharmaceutical company focused on the development and commercialization of treatments for rare diseases and unmet medical needs. As the United States subsidiary of Tokyo-based Nobelpharma Co., Ltd., the company leverages a specialized R&D approach to bring orphan drugs to market. Its lead commercial product, Hyftor (sirolimus topical gel), is the first FDA-approved topical treatment for facial angiofibroma associated with tuberous sclerosis complex. The company is dedicated to addressing "medical gaps" by developing therapies for conditions that are often overlooked by larger pharmaceutical firms.